Modulation of intracellular glutathione concentration alters dehydropyrimidine dehydrogenase activity in peripheral blood mononuclear cells

Clinical and Experimental Medicine

Volumn 2, Issue 2, 2002, Pages 99-103

  Iwata, S ^a,c   Takabayashi, A ^a   Yamaoka, Y ^b  

^a Kitano Hospital   (Japan)

^b KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c KYOTO CITY HOSPITAL   (Japan)

Author keywords

5 Fluorouracil; Dehydropyrimidine dehydrogenase; Glutathione; Peripheral blood mononuclear cells; Side effects

Indexed keywords

BUTHIONINE SULFOXIMINE; DEHYDROPYRIMIDINE DEHYDROGENASE; ENZYME; FLUOROURACIL; GLUTATHIONE; MERCAPTOETHANOL; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CELL LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME ACTIVITY; FEMALE; HUMAN; MALE; MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; STOMACH CANCER;

EID: 0036351283     PISSN: 15918890     EISSN: None     Source Type: Journal    
DOI: 10.1007/s102380200013     Document Type: Article

References (21)

1. Clinical pharmacology of 5-fluorouracil
2. Response to fluorouracil therapy in cancer patients: The role of tumoral dihydropyrimidine dehydroge-nase activity
3. Decreased dehydropyrimidine dehydrogenase activity in a population of patients with breast cancer: Implication for 5-fluorouracil-based chemotherapy
4. Dihydopyrimidine dehydrogenase activity and mRNA expression in advanced gastric cancer analyzed in relation to effectiveness of preoperative 5-fluorouracil-based chemotherapy
5. Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile
6. Correlation between dihydropyrimidine dehydrogenase activity in peripheral mononuclear cells and systemic clearance of fluorouracil in cancer patients
7. Oral administration of fluorouracil: A new approach utilizing modulators of dihydropyrimidine dehydrogenase activity
8. Characterization of the human dihydropyrimidine dehydrogenase gene
9. Lymphocyte proliferation modulated by glutamine: Involved in the endogenous redox reaction
10. Proliferative capacity of human peripheral blood lymphocytes sorted on the basis of glutathione content
11. Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion
12. Isolation of lymphocytes, granulocytes, and macrophages
13. A role for dihydropyrimidine dehydrogenase and thymidylate synthase in tumour sensitivity to fluorouracil
14. HPLC with o-phthalaldehyde pre-column derivatization to measure total, oxidized, and protein-bound gluthathione in blood, plasma, and tissue
15. Rapid colorimetric assay for cellular growth and survival-application to proliferation and cytotoxicity assays
16. Lymphocyte proliferation in glutathione-depleted lymphocytes: Direct relationship between glutathione availability and the proliferative response
17. Clinical implications of dihydropyrimidine dehydrogenase inhibition
18. Link between dihydropyrimidine dehydrogenase activity in peripheral blood mononuclear cells and liver
19. Putative role of dihydropyrimidine dehydrogenase in the toxic side effect of 5-fluorouracil in colorectal cancer patients
20. Dihydropyrimidine dehydrogenase deficiency and fluorouracil-related toxicity